Pharmacovigilance: Significance and challenges

Shruti Brahmbhatt; Mahavirsingh Rajput

doi:10.53730/ijhs.v6nS5.11201

Pharmacovigilance: Significance and challenges

https://doi.org/10.53730/ijhs.v6nS5.11201

Authors

Shruti Brahmbhatt
dr.shruti1988@gmail.com
Department of Pharmacology, Smt. B K Shah Medical Institute & Research Centre, Sumandeep Vidyapeeth deemed to be University, Piparia, Vadodara Gujarat, India
Mahavirsingh Rajput Department of Physiology, Smt. B K Shah Medical Institute & Research Centre, Sumandeep Vidyapeeth, Piparia, Vadodara

Keywords:

Adverse Drug Reaction, CDSCO, National Pharmacovigilance Programme, OTC, Pharmacovigilance programme of India, WHO

Abstract

The World Health Organization (WHO) defines Pharmacovigilance as the science & activities relating to detection, assessment, understanding and prevention of adverse effects or any other drug related problem. The National Pharmacovigilance Programme (NPVP) was launched in 2004 with World Bank funding till 2009, which was renamed as Pharmacovigilance Programme of India (PvPI). With advancement in the field of science and technology, India is emerging as a hub for clinical trials and new drug development, which challenges the monitoring of safety concerns in the use of new drugs. It has been difficult to identify or track the adverse drug reactions (ADRs) that occur in the patients due to polypharmacy, use of over the counter (OTC) preparations, change in physician etc. Hence the national programme has gained importance in our country off late. Yet it is observed that the importance of this programme is not realized by all health care professionals. Therefore, to support & strengthen the national programme which aims to identify, report & analyze the identified ADRs, it would be essential to sensitize the health care professionals through various means & faculty development programmes.

Downloads

Download data is not yet available.

References

Gupta SK, Editors. Textbook of Pharmacovigilance.1st ed. Jaypee 2011;p.1-78.

Ghosh Ak, De A, Bala NN. Current problems and future aspects of pharmacovigilance in India. International Journal of Pharma and Bio Sciences . 2011;1(2):15-28.

Kumar A. Past, present and future of pharmacovigilance in India. Syst Rev Pharm 2011;2:55-8.

Schmiedl S, Rottenkolber M, Hasford J, Rottenkolber D, Farker K, Drewelow B, Hippius M, Saljé K, Thürmann P. Self-medication with over-the-counter and prescribed drugs causing adverse-drug-reaction-related hospital admissions: results of a prospective, long-term multi-centre study. Drug Saf. 2014 Apr;37(4):225-35. doi: 10.1007/s40264-014-0141-3. PMID: 24550104.

Misra AK, Thaware P, Sutradhar S, Rapelliwar A, Varma SK. Pharmacovigilance: Barriers and challenges. Mintage journal of Pharmaceutical & Medical Sciences. 2013;35-36.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Mulkalwar S, Worlikar PS, Munjal N, Behera L. Pharmacovigilance in India.Medical journal of Dr.D.Y.Patil university.2013 June;2

Gandamayu, I. B. M., Antari, N. W. S., & Strisanti, I. A. S. (2022). The level of community compliance in implementing health protocols to prevent the spread of COVID-19. International Journal of Health & Medical Sciences, 5(2), 177-182. https://doi.org/10.21744/ijhms.v5n2.1897

Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64:743–52.

Sleath B, Svarstad B, Roter D. Physician motivation for non-scientific drug prescribing. Soc Sci Med. 1997;44:541–8.

Published

28-07-2022

How to Cite

Brahmbhatt, S., & Rajput, M. (2022). Pharmacovigilance: Significance and challenges. International Journal of Health Sciences, 6(S5), 5860–5863. https://doi.org/10.53730/ijhs.v6nS5.11201

Download Citation

Issue

Vol. 6 No. S5 (2022)

Section

Peer Review Articles

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.